09.04.25 -- Is AI Making Biologics Outsourcing Smarter?

Discover how Nanoform's patented Bio platform is revolutionizing biologics and peptide delivery. In this webinar, explore two breakthrough case studies—subcutaneous Trastuzumab with improved stability and syringeability, and inhalable Semaglutide for deep lung delivery. Learn how these innovations can boost patient comfort, compliance, and outcomes. Don’t miss insights shaping the future of patient-friendly therapies. Click here to learn more.

CMOs play a critical role in regulatory compliance for parenteral manufacturing, using audits, quality systems, and proactive strategies to ensure product safety and patient well-being.

To safeguard the consistent delivery of essential therapies to patients around the world, biopharmaceutical companies, alongside their CDMO partners, are rethinking traditional supply models.

A properly executed virtual audit facilitates thorough qualification, condenses production timelines, enhances relationship-building, and provides early insight into a CDMO’s capability and expertise.

This continues our discussion of AI and CDMOs, focusing on biologics and cell and gene therapy (CGT) relationships.

Next Generation Sequencing (NGS) offers a sensitive, high-throughput solution for detecting adventitious viral agents (AVAs), improving safety and accelerating regulatory-compliant product development.

Dive into the evolution and future potential of microbial manufacturing in the biopharmaceutical industry to discover how digital tools can revolutionize development and production processes.

Explore the benefits of prefilled syringes to enhance product convenience, reduce drug waste, and streamline your pharmaceutical manufacturing process.

Enable a wide array of genomic manipulation with the more regulated and efficient genomic insertion that's made possible by transposase-based technologies.

Discover how our process development team resolved a racemization challenge by delivering a biologically active racemic mixture while maintaining compound purity.

Evaluating your system’s performance and compatibility earlier in development can ensure you have a viable product to support development phases.

We discuss the trends in new molecular formats, which is one of the current drivers of renewed interest in fermentation technologies, along with some of their challenges. 

Gain insight into a CDMO with global, end-to-end mammalian manufacturing solutions, flexible capacity, and a strong track record in regulatory compliance that can support your company's needs.

Pedro Morales, Director, Scientific Advisor of Biologics Analytical Services, shares more on the process to deliver tailored solutions through deep expertise and advanced capabilities.

Discover a robust manufacturing platform that is meticulously designed to produce high-quality biologic drug substance. Each unit operation is carried out under strict cGMP conditions.

As pressure to accelerate timelines mounts, finding a CDMO committed to increasing capacity and optimizing processes is key for adding efficiency while maintaining high quality standards.

Leveraging deep ADC expertise and experience, successfully develop high quality, commercially viable processes, spanning from pre-clinical development through commercial scale manufacturing.